Prevymis is indicated Prophylaxis (prevention) of CMV infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT) who are at high risk for CMV reactivation. CMV infection is a complication in these patients, and early CMV reactivation after transplant is associated with increased mortality.
Cytomegalovirus (CMV) infection, a common herpesvirus infection with a wide range of symptoms: from no symptoms to fever and fatigue (resembling infectious mononucleosis) to severe symptoms involving the eyes, brain, or other internal organs.
“The agreement with Royalty Pharma reflects the major medical need for innovative anti-infective drugs and their commercial potential, and enables us to further advance our proprietary pipeline of novel treatments against infectious diseases without losing the possibility to participate on future revenues from Prevymis,” said Dr. Holger Zimmermann, CEO of AiCuris Anti-infective Cures GmbH.
“We are excited to add a royalty interest in this important therapy to our portfolio,” said Pablo Legorreta, Founder and CEO of Royalty Pharma.
Cytomegalovirus (CMV) infection